Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Natural killer cell based immunotherapy for eradication of minimal residual disease in patients with malignant disorders

Natural killer cell based immunotherapy for eradication of minimal residual disease in patients... Natural killer (NK) cells are cytotoxic against a variety of transformed and virus-infected cells. Cytotoxicity of NK cells is regulated through complex interactions between receptors expressed on NK surface and their cognate ligands expressed on the surface of target cells. A large body of data supports the concept that NK are key players of immune surveillance against cancer, and NK cell based immunotherapy has been proved to be feasible and effective. Allogeneic NK cell infusion, in nontransplant recipients with malignant disorders, is associated with a modest but of a short-term duration antitumor effect. The major limitation of allogeneic-NK therapy is the inevitable rejection of allogeneic effectors and the termination of antitumor activity. Allogeneic NK cells are not rejected by the host if infused after stem cell transplantation from the same donor. Although the existing data are limited, allogeneic-NK immunotherapy is much more effective if performed after haploidentical stem cell transplantation. Future trials should address this issue. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

Natural killer cell based immunotherapy for eradication of minimal residual disease in patients with malignant disorders

Download PDF
3 pages

Loading next page...
 
/lp/springer-journals/natural-killer-cell-based-immunotherapy-for-eradication-of-minimal-R8t3ZuVCEM
Publisher
Springer Journals
Copyright
Copyright © 2012 by Springer-Verlag Wien
Subject
Medicine & Public Health; Medicine/Public Health, general; Oncology
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-012-0010-7
Publisher site
See Article on Publisher Site

Abstract

Natural killer (NK) cells are cytotoxic against a variety of transformed and virus-infected cells. Cytotoxicity of NK cells is regulated through complex interactions between receptors expressed on NK surface and their cognate ligands expressed on the surface of target cells. A large body of data supports the concept that NK are key players of immune surveillance against cancer, and NK cell based immunotherapy has been proved to be feasible and effective. Allogeneic NK cell infusion, in nontransplant recipients with malignant disorders, is associated with a modest but of a short-term duration antitumor effect. The major limitation of allogeneic-NK therapy is the inevitable rejection of allogeneic effectors and the termination of antitumor activity. Allogeneic NK cells are not rejected by the host if infused after stem cell transplantation from the same donor. Although the existing data are limited, allogeneic-NK immunotherapy is much more effective if performed after haploidentical stem cell transplantation. Future trials should address this issue.

Journal

memo - Magazine of European Medical Oncology – Springer Journals

Published: Jun 5, 2012

References

  • The role of natural killer cells in immune surveillance of cancer
    Whiteside, TL; Herberman, RB
  • Human natural killer cell deficiencies
    Orange, JS
  • Fatal varicella associated with selective natural killer cell deficiency
    Etzioni, A; Eidenschenk, C; Katz, R; Beck, R; Casanova, JL; Pollack, S
  • NK cell receptors
    Lanier, LL
  • The role of natural killer cells in hematopoietic stem cell transplantation
    Tsirigotis, PD; Resnick, IB; Shapira, MY
  • Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer
    Rosenberg, SA; Lotze, MT; Muul, LM
  • Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma
    Law, TM; Motzer, RJ; Mazumdar, M
  • A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma
    Leemhuis, T; Wells, S; Scheffold, C; Edinger, M; Negrin, RS
  • Expansion of cytotoxic effectors with lytic activity against autologous blasts from acute myeloid leukaemia patients in complete haematological remission
    Torelli, GF; Guarini, A; Palmieri, G
  • Evidence that continued remission in patients treated for acute leukaemia is dependent upon autologous natural killer cells
    Lowdell, MW; Craston, R; Samuel, D
  • Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants
    Ruggeri, L; Capanni, M; Urbani, E
  • Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation
    Ruggeri, L; Capanni, M; Casucci, M
  • Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer
    Miller, JS; Soignier, Y; Panoskaltsis-Mortari, A
  • Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients
    Curti, A; Ruggeri, L; D’Addio, A
  • Immunotherapy in high-risk chemotherapy-resistant patients with metastatic solid tumors and hematological malignancies using intentionally mismatched donor lymphocytes activated with rIL-2: a phase I study
    Slavin, S; Ackerstein, A; Or, R
  • Treatment of resistant leukemia by rIL-2 activated NK cells in recipients of HLA matched and haploidentically mismatched stem cell allografts while avoiding GVHD
    Slavin, S; Or, R; Aker, M
  • Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation
    Passweg, JR; Tichelli, A; Meyer-Monard, S
  • IL-2 activated NK cell immunotherapy of three children after haploidentical stem cell transplantation
    Koehl, U; Sörensen, J; Esser, R
  • Adoptive immunotherapy with cytokine-induced killer cells for patients with relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation
    Laport, G; Sheehan, K; Baker, J